Due to a measles case in the community, please call before coming to Seattle Children’s if you or your child has potential measles symptoms.

Masking and Visitation Changes: Due to high rates of respiratory illnesses in our community, we’ve made changes to our masking and visitation guidelines .

Current Research Studies

Guanfacine for Hyperactivity in Children with Down Syndrome

HYPEbeGONE_DS

Phase: II
Clinicaltrials.gov ID: NCT06042257

What is the goal of the study?

1. Determine efficacy of guanfacine immediate release (GIR) for the treatment of hyperactivity/impulsivity and inattention in children with Down syndrome after 8 weeks of treatment. 2. Characterize the safety of guanfacine immediate release in children with Down syndrome

Who can participate in the study?

Children ages 6-12 years old with Down syndrome and hyperactivity/ADHD

Study Team:

PI (Study Doctor): Julia Mattson
Study Team Member: Alyssa Taira, [email protected]

Seattle Children’s complies with applicable federal and other civil rights laws and does not discriminate, exclude people or treat them differently based on race, color, religion (creed), sex, gender identity or expression, sexual orientation, national origin (ancestry), age, disability, or any other status protected by applicable federal, state or local law. Financial assistance for medically necessary services is based on family income and hospital resources and is provided to children under age 21 whose primary residence is in Washington, Alaska, Montana or Idaho.